Cell and gene therapies represent both sides of modern healthcare — the hopeful and the concerning. They advance the science of medicine, treating and curing diseases that we struggled to address in the past.
Some therapeutic sectors saw their compound annual growth rate drop 10% or more, deviating from long-term trends. Sales should return to normal growth trajectories as backlogs in procedures continue to clear out.
Merck executives share their strategy for embedding health equity across the pharma value chain.
As the Biden administration leans into the Cancer Moonshot 2.0, the life sciences industry has the opportunity to launch a new era of precision oncology. How can we accelerate progress toward truly personalized medicine and revolutionize cancer care?
Overheard at the J.P. Morgan Healthcare Conference
Executives detailed plans to take on more risk, build on advances in life sciences, and expressed optimism in Medicare Advantage, despite missing enrollment targets.
Pharmaceutical giants are shedding business units with an eye toward focusing on their innovative pharma operations and targeted therapeutic areas.
Life sciences companies need to be more engaged in building partnerships that promote high-value care.
Imagine a future where leveraging our DNA and what we know about it prevents illness and improves care outcomes.
And How Stakeholders Can, Literally, Save the World
Climate change will be the biggest impact on global health. The healthcare industry may not respond in time.
New Predictions on COVID-19 Vaccines and Herd Immunity
How COVID-19 case counts and vaccines may get us back to normalcy by June.